T. Kühbacher

发表

Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.

J. Hampe, S. Schreiber, R. Häsler, 2012, Journal of Crohn's & colitis.

Detection of Diverse Bacterial Signatures in Atherosclerotic Lesions of Patients With Coronary Heart Disease

Alexander Reinecke, Jochen Hampe, Ateequr Rehman, 2006, Circulation.

Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver

R. Lichtinghagen, K. Böker, T. Kühbacher, 1998, Virchows Archiv.

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

A. Forbes, S. Schreiber, C. Probert, 2003, Gut.

Mechanisms in failure of infliximab for Crohn's disease

S. Nikolaus, U. Fölsch, T. Kühbacher, 2000, The Lancet.

TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells.

P. Rosenstiel, D. Seegert, G. H. Waetzig, 2003, Gastroenterology.

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

S. Vermeire, L. Peyrin-Biroulet, W. Sandborn, 2019, Gastroenterology.

Pharmacogenetic association between the TNF receptor 2 genotype and response to infliximab treatment in Crohn disease

J. Hampe, H. Herfarth, S. Mascheretti, 2001 .

Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib

S. Vermeire, W. Reinisch, X. Hébuterne, 2022, Tissue barriers.

Pouchitis and the risk of cancer?

T. Kühbacher, 2001, International Journal of Colorectal Disease.

Ulcerative colitis: conservative management and long-term effects

U. Fölsch, T. Kühbacher, S. Schreiber, 2004, Langenbeck's Archives of Surgery.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

J. Langhorst, G. Rogler, F. Autschbach, 2019, Zeitschrift für Gastroenterologie.

Fungi and inflammatory bowel diseases: Alterations of composition and diversity

W. Weichert, P. Rosenstiel, K. Timmis, 2008, Scandinavian journal of gastroenterology.

Fungal rDNA signatures in coronary atherosclerotic plaques.

P. Rosenstiel, R. Simon, N. E. El Mokhtari, 2007, Environmental microbiology.

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

M. Kamm, P. Gionchetti, M. Campieri, 2006, Gut.

Activation of signal‐transducer and activator of transcription 1 (STAT1) in pouchitis

J. Hampe, P. Rosenstiel, H. Buhr, 2001, Clinical and experimental immunology.

Pouchitis: pathophysiology and treatment

T. Kühbacher, N. Runkel, S. Schreiber, 1998, International Journal of Colorectal Disease.

Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease.

F. Feuerhake, P. Rosenstiel, S. Rose-John, 2021, Gastroenterology.

Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study.

M. Christner, H. Rohde, M. Aepfelbacher, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

J. Mansfield, Fraser Cummings, T. Molnár, 2016, Alimentary pharmacology & therapeutics.

A comparison of oligonucleotide and cDNA-based microarray systems.

Hans Lehrach, Nancy Mah, Anders Thelin, 2004, Physiological genomics.

Approach to the Patient with Inflammatory Bowel Disease

T. Kühbacher, S. Schreiber, 2008 .

Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease

J. Hampe, P. Rosenstiel, A. Schottelius, 2002, Gut.

Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

N. Teich, A. Stallmach, S. Schreiber, 2018, Alimentary pharmacology & therapeutics.

TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells ☆ ☆☆ ★ ★★ ♢

P. Rosenstiel, D. Seegert, G. H. Waetzig, 2003 .

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

J. Langhorst, F. Autschbach, P. Kienle, 2020, Zeitschrift für Gastroenterologie.

CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue

Stefan Schreiber, M. Baggiolini, P. Gionchetti, 2004, International Journal of Colorectal Disease.

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

J. Hampe, M. Krawczak, H. Herfarth, 2002, The Pharmacogenomics Journal.

Infliximab in steroid-resistant ulcerative colitis – a randomised controlled trial.

A. Forbes, Subrata Ghosh, T. Kühbacher, 2003 .

Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin

P. Rosenstiel, R. Schmitz, Carolin Knecht, 2015, Gut microbes.

P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers.

L. Peyrin-Biroulet, T. Kühbacher, C. Lassen, 2017, Journal of Crohn's & colitis.

INFLAMMATION AND INFLAMMATORY BOWEL DISEASE Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease

A. Schottelius, D. Seegert, T. Kühbacher, 2002 .